Incyte Biosciences Canada today announced that Health Canada has approved Opzelura® (ruxolitinib (as ruxolitinib phosphate)) ...
The recent FDA approval of topical JAK inhibitors for children 2 years or older marks a significant advancement in pediatric ...
Experts discuss the foundational role of topical therapies in pediatric atopic dermatitis management, highlighting the ...
The Atopic Dermatitis Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key ...
Everyday Health on MSN
What to Wear When You Have Atopic Dermatitis: 5 Tips to Protect Your Skin
The right clothing can help you minimize atopic dermatitis flares. Learn about common clothing triggers, plus tips on ...
ZORYVE cream 0.05% provides rapid and effective relief of mild to moderate atopic dermatitis in children ages 2 to 5 and is safe and well toleratedOnce-daily, steroid-free cream can be used anywhere ...
This approval follows the recent FDA approval of ruxolitinib cream 1.5% (Opzelura), a topical JAK inhibitor, as a treatment ...
Zoryve cream gains FDA approval for treating mild to moderate atopic dermatitis in young children, offering a safe, ...
The FDA approved Zoryve cream 0.05% for the treatment of children aged 2 to 5 years with mild to moderate atopic dermatitis, ...
The FDA has approved Zoryve (roflumilast) cream 0.05% for the topical treatment of mild to moderate atopic dermatitis in children 2 to 5 years of age.
Explore the latest insights on canine atopic dermatitis treatment with Joya Griffin, DVM, DACVD, and Adam Christman, DVM, MBA.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback